Advances in metastatic bladder cancer do not come round every day, and it is big news when they do. The FDA approval of atezolizumab (Tecentriq) combined with the break-through therapy designation that nivolumab (Opdivo), things are on the upswing.
Cancer Research UK (CRUK) in conjunction with Astex has begun a Phase I/II Trial to measure the success of a DNA Methyltransferase (DNMT) inhibitor can halt the progress of bladder cancer proving resistant to chemotherapy.
Is it time for urologist to begin to rethink the radical cystectomy, and begin to explore trimodality therapy? Maybe, maybe not, depends on who you ask. Let’s go over a few things first before we jump right in though: